Protocol Name: A study to evaluate the efficacy and safety of frexalimab, brivekimig, and rilzabrutinib in patients with primary FSGS or minimal change disease
Protocol #: ACT18064
Indication: Fabry Disease
GFR: ≥ 45
Principal Investigator: Ankit N. Mehta, MD, FASN
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204